Relapsed Or Refractory Myeloma clinical trials

Explore recruiting relapsed or refractory myeloma clinical trials.

Recruiting relapsed or refractory myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

Sweden, Belgium, Austria, France, Czechia, Greece +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classes

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed Or Refractory Myeloma trials by city

Relapsed Or Refractory Myeloma in Toronto Relapsed Or Refractory Myeloma in Vancouver Relapsed Or Refractory Myeloma in Montreal Relapsed Or Refractory Myeloma in Calgary Relapsed Or Refractory Myeloma in Edmonton Relapsed Or Refractory Myeloma in Ottawa Relapsed Or Refractory Myeloma in Winnipeg Relapsed Or Refractory Myeloma in Quebec City Relapsed Or Refractory Myeloma in Hamilton Relapsed Or Refractory Myeloma in Kitchener Relapsed Or Refractory Myeloma in London Relapsed Or Refractory Myeloma in Halifax Relapsed Or Refractory Myeloma in New York Relapsed Or Refractory Myeloma in Los Angeles Relapsed Or Refractory Myeloma in Chicago Relapsed Or Refractory Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease